Rapamycin rapa

Manufactured by Tokyo Chemical Industry

Sourced in Japan

Rapamycin (RAPA) is a macrolide compound produced by the bacterium Streptomyces hygroscopicus. It functions as an immunosuppressant and has been used in various applications, including organ transplant rejection prevention and certain cancer treatments.

Automatically generated - may contain errors

Lab products found in correlation

Glycol chitosan, by Merck Group (1 mentions) Doxorubicin, by Merck Group (1 mentions) 1 2 dipalmitoyl sn glycero 3 phosphocholine, by Merck Group (1 mentions) Docosahexaenoic acid, by Merck Group (1 mentions) Cholesteryl hemisuccinate, by Merck Group (1 mentions) Z vad fmk z vad, by Selleck Chemicals (1 mentions) S63845, by Selleck Chemicals (1 mentions)

Spelling variants of this product

Rapamycin (12 citations)

2 protocols using rapamycin rapa

Lipid-based Nanocarrier for Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesteryl hemisuccinate (CHEMS), glycol chitosan (GC), docosahexaenoic acid (DHA), and doxorubicin (DOX) were purchased from Sigma-Aldrich (USA). Rapamycin (RAPA) was purchased from Tokyo chemical industry (Japan).

Kim M.W., Niidome T, & Lee R. (2019). Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer. Marine Drugs, 17(10), 581.

+ Open protocol

+ Expand

Mitophagy Induction and Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols

OR21 was synthesized by OHARA Pharmaceutical Co. AZA and DAC were purchased from Sigma-Aldrich. Ven and P62-mediated mitophagy inducer (PMI) were purchased from MedChemExpress. S63845, a selective myeloid cell leukemia-1 (MCL-1) inhibitor, and Z-VAD-FMK (Z-VAD) were purchased from Selleck Chemicals. Rapamycin (Rapa) was purchased from Tokyo Chemical Industry. All reagents were dissolved in DMSO and stored at −20°C.

Kamachi K., Ureshino H., Watanabe T., Yoshida-Sakai N., Fukuda-Kurahashi Y., Kawasoe K., Hoshiko T., Yamamoto Y., Kurahashi Y, & Kimura S. (2023). Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer Research Communications, 3(2), 297-308.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!